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Cardiac hypertrophy is an adaptive process that occurs in response to increased physical stress on the heart. Hypertrophy, which may be
induced by hypertension among other factors, is characterized by an increase in left ventricular mass and an associated increase in force production
capacity. However, as sustained cardiac hypertrophy may lead to heart failure and sudden death, an understanding of the molecular processes
involved in both the onset and consequences of hypertrophy is of significant importance. Calcium is a key player in the process underlying the
development of cardiac hypertrophy. Recently, several Transient Receptor Potential proteins (TRPs), including calcium-permeable and calcium-
regulated ion channels, have been shown to be related to various aspects of cardiac hypertrophy. TRPs are implicated in the development of
cardiac hypertrophy (TRPC1, TRPC3, TRPC6), the electrophysiological perturbations associated with hypertrophy (TRPM4) and the progression
to heart failure (TRPC7). This review describes the major characteristics of cardiac hypertrophy and focuses on the roles of TRPs in the
physiological processes underlying hypertrophy.
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1.1. Features of cardiac hypertrophy
Cardiac hypertrophy is characterized by an increase in left
ventricular mass and associated changes in the shape of the left
ventricle. It is an in vivo adaptive process that allows the
organism to maintain or increase its cardiac output. Never-
theless, in humans, a sustained cardiac hypertrophy can lead to
arrhythmias, heart failure and sudden death. Therefore, elucida-
tion of the molecular processes involved in both the onset and
consequences of hypertrophy is of great importance.
Hypertrophy is triggered by a wide array of processes in
response to increased workload induced by hypertension,
valvular dysfunction, myocardial infarction, genetic disease or
endocrine disorders [1,2]. As illustrated in Fig. 1, these
hypertrophy-causing conditions reactivate the foetal program
in cardiomyocytes. Hypertrophy-related gene expression has⁎ Corresponding author. Tel.: +33 5 49 45 37 47; fax: +33 5 49 45 40 14.
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doi:10.1016/j.bbadis.2007.02.007been reported for (i) cytoskeletal constituents such as β-myosin
heavy chain (β-MHC) and α-smooth muscle actin (α-sm actin);
(ii) several types of proteins involved in ion transport such as the
T-type calcium channel (ICa,T) and the hyperpolarization and
cyclic nucleotide-activated channel (HCN); (iii) secreted factors
such as atrial natriuretic factor (ANF) and angiotensin II; and (iv)
transcriptional factors [1]. In contrast, the expression of other
proteins like the sarcoplasmic reticulum Ca2+-ATPase (SERCA)
is repressed [3].Modifications to the expression of these proteins
can be manifested in terms of altered action potential shape,
altered calcium transient properties and changes to the
excitation–contraction coupling process. In addition, in cases
of pronounced hypertrophy, the proliferation of fibroblasts can
occur, thereby adding to the extent of cardiac dysfunction [4].
Concerning the implication of ion channels in cardiac
hypertrophy, two points need to be considered. First, the
phenomenon by which ion channels are involved in the
induction of hypertrophy (mechano-sensitive signal); and
second, modifications to the normal electrophysiological
properties of cardiomyocytes, which consequently give rise to
arrhythmias.
Fig. 1. Process of cardiac hypertrophy. Trigger signal for hypertrophy leads to
the expression of sarcomeric proteins responsible for cardiomyocyte hyper-
trophy. Modifications in the expression of proteins involved in ion transport give
rise to perturbations in the electrical activity of the cell.
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Among the modifications of gene expression induced by the
hypertrophic process are included genes for several channel
proteins involved in the electrophysiological properties of
excitable cells. Alterations to these electrophysiological proper-
ties can be evident in the electrocardiogram (ECG), where a
prolongation of the QT interval and also a modification of the
cardiac axis in the direction of hypertrophied ventricle are
common features associated with hypertrophy. Measurement of
the QT interval provides a non-invasive indication of the action
potential duration. Indeed, prolongation of the ventricular action
potential, in association with a sustained depolarization, has
been reported in numerous studies of hypertrophic remodelling
[4–7]. While depolarization of the resting membrane potential
is attributed to an alteration of the inward rectifier current IK1,
prolongation of action potential is mainly attributed to a
reduction in the transient outward current (Ito) density [8]. In
addition, the expression of other currents, such as the
pacemaker funny current If [9,10] and the transient calcium
current ICa,T [11] is increased during hypertrophy.
Literature reports highlight the altered expression during
hypertrophy of several proteins implicated in the Ca2+ transient;
these include SERCA, the ICa,T channel, the Na/Ca exchanger
[3,11,12] and calcium-permeable non-selective cation channels
(see following sections). The altered expression of these
membrane proteins results in a prolongation of the calcium
transient and an increase in the resting Ca2+ concentration. The
modification of Ca2+-dependant mechanisms appears to be the
major source of arrhythmias in hypertrophied heart.
1.3. Calcium signalling pathways in cardiac hypertrophy
While mechanisms underlying the onset of hypertrophy
remain largely unknown, Ca2+, however, appears to be a major
component of the phenomenon. An increase in calcium
signalling, which is observed in the first stages of hypertrophy,
is probably implicated in the induction of gene expression
modifications (see [13] for review). Thus, driven by extrinsicfactors, changes to the Ca2+ transient in terms of its frequency,
amplitude or width are considered to be the primary signal for
hypertrophy. Molecules that activate the phosphoinositide-
specific phospholipase C (PLC) pathway may trigger modifica-
tions to the Ca2+ transient by the generation of 1,4,5-trisphos-
phate (IP3) and diacylglycerol (DAG) followed by the release of
Ca2+ from the sarcoplasmic reticulum (SR). Protein expression
induced by this Ca2+ release may operate through several Ca2+-
dependent mechanisms. Calcineurin, a Ca2+ and calmodulin-
dependant protein phosphatase, was shown to be implicated in
the integrating pathway (see [14,15] for review). Additional
proteins transmit calcineurin-dependant signals to the nucleus
with consequent changes in gene transcription. The most well-
characterized substrate for calcineurin is the nuclear factor of
activated T cells (NFAT). Calcineurin dephosphorylates serine
residues of NFAT leading to its translocation from the cytoplasm
to the nucleus where it engages a variety of transcription factors,
leading to the activation of responsive genes. Several data
suggest that the depletion of SR Ca2+ stores itself is not solely
responsible for activating gene expression, but results in an
influx of extracellular Ca2+ into the cytoplasm, causing a
sustained elevation of the internal Ca2+ concentration. A link
between Ca2+ stores depletion, activation of the capacitive Ca2+-
entry and modification of gene expression via the calcineurin/
NFAT pathway was first demonstrated in T cells [16–18] and
later in myocytes [19]. It was also observed in heart preparations
where inhibition of store-operated Ca2+ currents prevents the
calcineurin-dependant nuclear translocation of NFAT [20,21].
It should be noted that, in addition to the Ca2+/calmodulin-
dependant protein phosphatase calcineurin, the Ca2+/calmodulin-
dependant proteins kinases I, II and IV are also able to induce
cardiac hypertrophy [22,23].
2. The Transient Receptor Potential (TRP) channel family
2.1. Molecular structure and regulation
From the above discussion, it appears that Ca2+ plays a
crucial role in the development of cardiac hypertrophy and of its
consequences. Thus the implication of Ca2+-permeable channels
in this process is of much interest.
The discovery of a novel family of cation channels, the
“transient receptor potential” (TRP) protein family, has provided
molecular support for a large variety of non-selective channels.
The TRP cation channels, which were first characterized in
tissue from the Drosophila eye, are classified for mammals into
6 subfamilies: TRPC (Canonical, 7 members), TRPV (Vanilloid,
6 members), TRPM (Melastatin, 8 members), TRPP (Poly-
cystin, 3 members), TRPML (Mucolipin, 3 members) and TRPA
(Ankyrin, 1 member) (see [24,25] for review). Most of the
proteins of the main subfamilies (TRPC, TRPV, TRPM) are
permeable to calcium and other cations (PCa/PNa=1–10).
However, some of these channels are strictly Ca2+-selective
(TRPV5, V6) andwere presented asmolecular candidates for the
epithelial Ca2+ current IECaC [26]. Other members are highly
Mg2+ selective (TRPM6 and TRPM7). In addition, those that are
not Ca2+-permeable (TRPM4 and TRPM5) were shown to be
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could be implicated in calcium signalling. This point was
recently extensively reviewed by Minke [26].
Concerning their molecular structure, all TRP channels are
composed of subunits containing 6 transmembrane segments
(TM1–6) that assemble as tetramers. The subunits have been
shown to homo-associate but also, in some cases hetero-
associate (see [24,25,29] for review). Thus great care should be
taken when comparing channel properties observed in over-
expressing systems and in native cells. Similarly to classical 6
TM channels, the channel pore, containing the selectivity filter
and channel gate is formed by the assembly of the four loops
linking TM5 to TM6. TRPs are considered as voltage-sensitive
channels. However, the paucity of positively charged residues
in TM4, the segment that confers voltage sensitivity to classical
voltage-gated channels, suggests that the voltage sensitivity of
TRPs uses a distinct mechanism. The intra-cytoplasmic C and
N-terminal segments hold a variety of specific sites that differ
from one TRP to the other and thus address specific regulatory
properties. As such, a large variety of TRP activity modulators
have been described in the literature and already extensively
reviewed [24,25,29]. These modulators include intracellular or
extracellular molecular components as well as biophysical
modulators such as voltage or temperature. They work by
activating G protein-coupled receptors or tyrosine kinase
receptors; the production of DAG or IP3 subsequently induces
the liberation of Ca2+ from intracellular stores. Direct activation
of TRPs by ligands has also been reported. These ligands
consist of exogenous organic molecules such as capsaicin or
menthol, endogenous lipids such as DAG or phosphoinositides,
purine nucleotides such as ATP or ADP-ribose and inorganic
ions such as Ca2+ or Mg2+. TRPs are also regulated by a large
number a kinases including PKA, PKC, PKG and the Ca2+/
calmodulin pathway.
2.2. Physiological implications of TRPs: calcium signalling
and voltage modulation
Due to their large number and the diversity of their
modulators, TRPs are implicated in a variety of physiological
processes and serve, in particular, as signal integrators. In
addition, these channels are considered as signal amplifiers.
Indeed, they serve as molecular candidates for a variety of Ca2+
currents such as store-operated Ca2+-entry channels (SOCs),
receptor-operated Ca2+-entry channels (ROCCs) and stretch-
activated channels (SACs). In particular, TRPs may be
implicated in the phenomenon called store-operated calcium
entry (SOCE) involved in several cellular functions including
responses that are dependant upon Ca2+ entry into the cell.
Activation of plasma membrane receptors coupled to PLC leads
to the production of IP3, triggering intracellular calcium-store
depletion. This depletion activates SOCE through plasma
membrane proteins as SOCs. The pathway that links Ca2+
release from the SR to store-operated Ca2+ current activation is
not known precisely. A number of mechanisms have been
proposed, such as the diffusion of a soluble Ca2+ influx factor
(CIF), the conformational coupling of activated IP3-receptors tothe channel mediating the Ca2+ entry, the fusion to the plasma
membrane of cytoplasmic vesicles transporting Ca2+-entry
channels [30], and recently, involvement of the single spanning
membrane protein STIM1 [31–33].
While still being debated, several lines of evidences support
the idea that some TRPs may correspond to SOCs. Each of the
TRP subfamilies likely hosts some members that can be
activated by the depletion of intracellular calcium stores. This
point will be detailed in the following sections concerning
specific TRP channels implicated in cardiac hypertrophy.
TRP channels should also be regarded as membrane
potential modulators. Because of their non-selective cation
selectivity, opening of TRPs in a negative resting membrane
potential will generally produce a depolarizing current. This
property could be used in particular in excitable cells that
possess a variety of voltage-sensitive channels that could thus
be modulated by the membrane potential variation.
In the following sections, we focus attention on TRPs
channels that have been implicated in cardiac hypertrophy,
providing a brief description of their biophysical properties and
reviewing their contribution to hypertrophy. This contribution
should be regarded first as a pathway for extracellular Ca2+
entry into the cell, but also as a depolarizing component.
3. TRP channels in cardiac hypertrophy
In the heart, the presence of several TRPs – TRPC1,
TRPC3–7, TRPV1, TRPV2, TRPV4, TRPM4, TRPM6,
TRPM7 and TRPP2 – has been reported [34,35]. However, it
is important to note that these channels were mostly detected by
RT-PCR or by biochemical studies on the whole heart, meaning
that the cellular expression profile and functional expression of
the channels are thus yet to be determined. In fact, only six types
of TRP currents have been recorded in the heart. These currents
are associated with TRPC1, TRPC3 and TRPC6, three store-
operated Ca2+-channels expressed in mouse or rat ventricle
implicated in calcineurin-dependant cardiomyopathies [36–39];
TRPM4, a Ca2+-activated non-selective cation channel present
in human atrial cardiomyocytes and ventricle from hypertro-
phied rat hearts [40,41]; and TRPM6 and TRPM7, which are
responsible for a Mg2+-inhibited cation current (IMIC) in pig,
guinea-pig and rat ventricular cardiomyocytes [42,43].
A large number of animal models of cardiac hypertrophy
have been described in the literature, the majority of which have
been developed in an effort to mimic the human condition (see
[1,44] for review). These models include: (i) animals that have
undergone a surgical procedure such as coronary ligation or
aortic banding; (ii) animals that develop systemic hypertension
after receiving a high-salt diet or injections of pharmacological
agents; (iii) genetically selected animals such as spontaneously
hypertensive rats (SHR) or the spontaneous hypertensive heart
failure (SHHF) rat; (iv) development of adult rat cardiomyocytes
in culture; and (v) transgenic animals that lack or over-express
one of the proteins involved in the control of hypertrophy.
Several recent studies using these models showed the
implication of TRPs in both the development of hypertrophy
and its consequences including the triggering of arrhythmias.
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TRP involved and summarized in Table 1.
3.1. TRPC1
One candidate for the SOCE pathway is TRPC1, which was
the first member of the TRPC family to be cloned. This
membrane protein is a 16 pS non-selective cation channel with
similar permeabilities for Na+ and Ca2+ and was shown to be
activated by calcium store depletion when expressed in CHO or
Sf9 cells [45]. Later, the implication of TRPC1 in SOCE and
subsequent NFAT activation was demonstrated in B lympho-
cytes [46]. In two recent studies, Ohba et al. [38,39] similarly
observed that overexpression of TRPC1 in HEK 293T cells
increased SOCE, leading to a rise in NFAT promoter activity.
Subsequently, using primary cultures of neonate rat cardio-
myocytes, these authors observed an increase in the expression
of TRPC1 and SOCE associated with cell hypertrophy induced
by endothelin 1 treatment. This augmentation of TRPC1
expression associated with cardiac hypertrophy was also
observed in abdominal aortic-banded rats that developed
cardiac hypertrophy [39]. In contrast, silencing of the TRPC1
gene via small interfering RNA (siRNA) attenuates SOCE and
prevents cardiac hypertrophy [39]. These results highlight the
role of TRPC1 as an important regulator of cardiac hypertrophy
through its SOC properties.
3.2. TRPC3
Another candidate to support SOCE is TRPC3. This protein
is a non-selective cation channel with a single channel
conductance around 25 pS [30]. It is a poor discriminator of
Na+ over Ca2+ (PCa/PNa=1.6). In neurons, TRPC3 appears to
be an integral component of a signal transduction cascade
involving PLCγ, the generation of IP3 and an increase in [Ca
2+]i
[47]. It belongs to the DAG-sensitive TRPC3/6/7 subfamily.
While its classification as a SOC channel is still being debated
(see [30] for review), activation of NFAT was shown to beTable 1
Incidence of TRP channels in cardiac hypertrophy
Models used to investigate the incidence of TRPs in cardiac hypertrophy. Hyp.=hyincreased in myocytes transfected with TRPC3 expression
plasmid [19].
The contribution of the TRPC3 channel to capacitive Ca2+
entry has recently been highlighted in two cardiac models. In
one study, Bush et al. [48,49] used microarray analysis to
examine the pattern of expression of a variety of genes from
cultured cardiomyocytes exposed to the α-adrenergic receptor
agonist phenylephrine, which is considered capable of inducing
cellular hypertrophy. Among the genes most potently modified,
TRPC3 is upregulated. Using several animal models of
hypertrophy, including cultured neonatal rat ventricular myo-
cytes, SHHF rats and isoproterenol-induced heart hypertrophic
rats, Bush et al. [48] investigated the contribution of the TRPC3
channel to the development of hypertrophy. They used an
adenoviral strategy to induce the over-expression of TRPC3 in
cultured cardiomyocytes, and observed a weak sarcomere
assembly that was increased in the presence of oleoyl-2-acetyl-
sn-glycerol (OAG), a molecule known to activate several TRP
channels including TRPC3 [50]. In addition, TRPC3 over-
expression produced an increase in cell volume, as well as an
upregulation of ANF and α-sm actin mRNA transcripts, two
markers of hypertrophy. The use of the SOC inhibitor
2-aminoethoxydiphenylborane (2-APB) reduced the α-adrener-
gic receptor agonist-stimulated ANF secretion and cell volume
increase. Furthermore, a link between TRPC3 and calcineurin
was demonstrated by immunoblotting studies showing that
TRPC3 stimulates NFAT. Together, the results demonstrate that
TRPC3 expression is increased in hypertrophy, and that it is
implicated in the development of hypertrophy via calcineurin/
NFAT signalling.
The implication of TRPC3 in hypertrophy was also elegantly
demonstrated by another group using TRPC3 over-expressing
transgenic mice [36]. Adult cardiac myocytes isolated from
these mice showed abundant store-operated Ca2+-entry that was
inhibited by SKF96365, a known inhibitor of SOCs. In
addition, transgenic mice showed an increase in NFAT
activation in vivo, as well as cardiomyopathy and augmented
hypertrophy after neuroendocrine agonist application orpertrophy.
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ment, the cardiomyopathic phenotype and the increased
hypertrophy after pressure overload stimulation were blocked
by targeted disruption of the calcineurin Aβ gene. In contrast,
siRNA silencing of TRPC3 in cultures of rat neonate cardio-
myocytes suppresses angiotensin II-induced NFAT transloca-
tion [37]. A schema summarizing the possible role of TRPC3 in
cardiac hypertrophy is proposed in Fig. 2.
In association with TRPC3, it is also probable that the Na+/
Ca2+ exchanger participates in the increase of [Ca2+]i. Indeed, it
was reported that a local coupling existed between the two
proteins when expressed in HEK293 cells [51]. Ca2+ entry into
TRPC3-expressing cells involves the reversed mode of the Na+/
Ca2+ exchanger. In addition, co-immunoprecipitation experi-
ments provided evidence of the association of these two
proteins.
3.3. TRPC6
In addition to TRPC1 and TRPC3, TRPC6 was also recently
revealed to be involved in calcineurin-NFAT signalling both
upstream and downstream of NFAT. Kuwahara et al. [52],
followed the cardiac expression of TRPCs using transgenic
mice harbouring an α-MHC-calcineurin transgene, which
results in cardiac hypertrophy. They detected TRPC1,3,4,6
transcripts and among these observed that TRPC6 expression
was upregulated in the hypertrophied hearts. Consistent with
these findings, the promoter of the TRPC6 gene contains 2
NFAT-binding sites. On the other hand, cardiac-overexpression
of TRPC6 in transgenic mice resulted in an increase in NFAT-
dependant expression of β-MHC, considered as a marker of
pathologic hypertrophy [52]. At the opposite, siRNA knock-
down of TRPC6 reduced hypertrophic signalling induced by
phenylephrine and endothelin-1 [52]. These data are inFig. 2. Implication of TRP channels in the proposed mechanism of cardiac hypertroph
activated phospholipase C (PLC) cleaves phosphatidylinositol 4,5-bisphosphate (P
depletion of the sarcoplasmic reticulum (SR), triggered by the binding of IP3 to its
unknown mechanism. Direct activation by DAG is also involved. Activation of TRP
potential (Δψ) in favour of the activation of L-type Ca2+-currents. Capacitive Ca2+-en
type Ca2+-currents, activates calmodulin (CaM) which couples with calcineurin to dep
activated channels (SACs) may also contribute to the rise in intracellular calcium. On
expression. One of these genes is for the TRPC6 protein. Another may be for the TRP
of Ca2+ and DAG in the sarcoplasm, thus inducing arrhythmias.accordance with the implication of the channel in activation
of the calcineurin-NFAT pathway in response to G protein-
coupled receptor signalling. The pathway that links G protein to
channel activation was investigated in rat neonatal cardiomyo-
cytes. In this model, the PLC-mediated production of DAG was
found to be essential for Angiotensine II-induced NFAT
activation [37]. TRPC3, TRPC6 and TRPC7 belong to the
DAG-activated TRP channels. The activity of TRPC3 and
TRPC6 seems to be correlated with Angiotensine II-induced
NFAT activation and hypertrophic process but not TRPC7. The
effects of these channels may include both an increase in
calcium entry through the channel as well as membrane
depolarization, which activates voltage-gated calcium perme-
able channels such as the L-type Ca2+ channel [37].
3.4. TRPC4 and TRPC5
A crucial role in modifying [Ca2+]i in cardiac hypertrophy
has been demonstrated, until now, only for TRPC1, TRPC3 and
TRPC6. However, experimental data suggest the possible
contribution of other TRP members. The reduction of SERCA
expression during hypertrophy (see Section 1.1) could induce
an increase in TRPC4 and TRPC5 expression. Indeed, down-
regulation of cardiac SERCA2 in cardiomyocytes in culture
using interfering RNA is followed by increased transcription of
the Na+/K+ exchanger, TRPC4, TRPC5 and NFAT [53]. Un-
fortunately, TRPC3 expression was not investigated in that
study. However, the study's findings suggest a link between the
regulation of Ca2+ reuptake and expression of proteins involved
in [Ca2+]i regulation. One could therefore postulate that TRPC4
and TRPC5 are implicated in the process. Interestingly, it was
observed that TRPC5 mRNA and protein expression were
significantly elevated in failing human heart relative to non-
failing controls [48]. In contrast, TRPC3 was detectable iny. After binding of a hypertrophic factor to a Gq protein-coupled receptor (R), the
IP2) into inositol-1,4,5 trisphosphate (IP3) and diacylglycerol (DAG). Ca
2+-
receptor (IP3R), activates the TRPC3,6 store-operated channels (SOC) by an
C1,3,6 produces an inward depolarizing current, thus modifying the membrane
try through TRPC1,3,6, in addition to the Ca2+ provided by SR depletion and L-
hosphorylate nuclear factor of activated Tcells (NFAT). Ca2+-permeable, stretch-
ce activated, NFAT is able to enter the nuclear compartment (N) to induce gene
M4 channel, which carries a depolarizing current activated by the elevated levels
890 R. Guinamard, P. Bois / Biochimica et Biophysica Acta 1772 (2007) 885–894neither non-failing nor failing human heart. Thus it could be
suggested that, due to species specificity, TRPC5 might be
expressed during human heart remodelling as opposed to
TRPC3 in rat or mouse.
In addition to their role in the induction of cardiac hyper-
trophy, TRPs could also provide new influx pathways for both
Na+ and Ca2+ during the action potential and thus modify its
shape. The relation between the reduction of SERCA, a hallmark
of cardiac hypertrophy, and the rise in the expression of TRP
proteins (TRPC4–5) is also a source of potent electrophysiolo-
gical perturbations [53].
3.5. TRPM4
Amajor cellular perturbation during cardiac hypertrophy is the
increase in [Ca2+]i. This induces an activation of Ca
2+-dependant
mechanisms, including the activation of Ca2+-sensitive channels.
Among these, we reported a functional overexpression of the
TRPM4 protein in rat ventricular cardiomyocyte during hyper-
trophy [41].
TRPM4 is a calcium-activated non-selective cation channel.
When expressed in HEK293 cells, it displays a linear current/
voltage relationship with a conductance of 25 pS [27]. It is
activated by membrane depolarization [54] and by an increase in
[Ca2+]i for which the concentration for half maximal activation
ranges between 0.4 [27] and 9.8 μmol/L [55]. This Ca2+
sensitivity is modulated by PKC-dependant phosphorylation
[56]. The channel is equally permeable to Na+ and K+, but in
contrast to all other TRPs except TRPM5, it is not permeable toFig. 3. TRPM4 expression induced by hypertrophy of cardiomyocytes in culture. Adu
week in culture as shown by an increase in cell capacitance and strong modification o
and, by that time, the resting membrane potential becomes less negative [68]. Thes
[66,69].Ca2+. It is blocked by intracellular adenine nucleotides including
ATP. These properties are in accordance with its molecular
structure, which displays a range of functional sites in its
intracellular loop domains, such as six PKC phosphorylation
sites, four ATP binding sites and five calmodulin binding sites
[56]. TRPM4 mRNA is expressed in a variety of mammalian
cells with a heightened expression in the heart and kidney
[27,54]. Taken together, the TRPM4 fingerprint matches very
closely the properties of several Ca2+-activated non-selective
cation currents described in a large variety of tissues [57]. In the
heart, it was detected in human atrial cells [40] andmore recently
in mouse sinoatrial node cells (see [58,59] for review). In the
ventricular cells, its expression is amplified during cardiomyo-
cyte hypertrophy.
Our first indication that TRPM4 is over-expressed during
cardiac hypertrophy came from work done on adult rat
ventricular cardiomyocytes in culture. This model is a suitable
in vitromodel for detailed analysis of hypertrophy at the cellular
level. Indeed, during the culture, the foetal program of gene
expression is reactivated, mimicking events associated with
hypertrophy in vivo [60–65]. While absent from freshly isolated
cells, TRPM4 was detectable in more than half of the excised
patches from dedifferentiated cells after 1 week of culture [66].
As indicated in Fig. 3, an increase in cell capacitance as the time
in culture progresses provides an indication of hypertrophy. At
the same time, the resting membrane potential becomes less
negative and spontaneous beating is observed after 1 week in
culture [61,62,64,67,68]. Depolarization of the normal resting
membrane potential is consistent with the modifications madelt rat ventricular cardiomyocytes undergo a process of hypertrophy with the first
f cell shape [61]. Spontaneous electrical activity develops after cell remodelling
e phenomena are correlated with an increase in TRPM4 functional expression
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cell dedifferentiation, together with a reduction in the back-
ground potassium current (IK1). Nevertheless, it is feasible that
the TRPM4 current also participates in the mechanism of
membrane potential depolarization, which in turn would explain
the triggering of spontaneous beating. TRPM4 could also be
implicated in the prolongation of action potential duration
reported to be present in the hypertrophied heart. Interestingly,
for the myocyte culture model, we also observed that the Ca2+-
activated non-selective cation current is activated by DAG
analogues. This is achieved not only by PKC-dependent
activation, but also by a PKC-independent pathway that is
probably a direct interaction of the analogues, as reported for
other TRP channels [69]. These regulations should be
physiologically significant given that both DAG content and
PKC activity increase during hypertrophy [70,71].
Further investigations have confirmed TRPM4 expression
during cardiac hypertrophy by using freshly isolated ventricular
cardiomyocytes from spontaneously hypertensive rats (SHR), a
well-established genetic model of hypertension and cardiac
hypertrophy when compared to its normotensive equivalent, the
Wistar–Kyoto (WKY) rat. We functionally detected the current
and also studied the presence of TRPM4 mRNA in ventricular
tissue from both SHR and WKY rats [41]. The level of TRPM4
mRNA is much higher in SHR than in WKY rats. In parallel we
observed an increase in functional detection of the TRPM4
current (Fig. 4). Channel detection was proportional to the
heart-to-body weight ratio, showing that TRPM4 detection is
not due to genetic selection of the rat population but rather
related to the development of hypertrophy. TRPM4 is thus
expressed during ventricular remodelling in SHR and could
participate in some features of cardiac arrhythmias associated
with hypertrophy.
Minimal data are available concerning Ca2+-activated non-
selective cation currents at the macroscopic level, probably dueFig. 4. TRPM4 expression in ventricular cardiomyocytes from SHRs. While
TRPM4 mRNA is weakly detected in ventricular myocytes from normotensive
WKY rats, it is highly detectable in tissue from hypertensive SHR animals that
develop cardiac hypertrophy as shown by the increase in heart/body weight
ratio. This expression is functional as TRPM4 current is recordable in SHR but
not in WKY cardiomyocytes. It is postulated that cardiac hypertrophy induces
TRPM4 expression which in turn participates in the triggering of arrhythmias
[41].to the difficulty involved to clearly isolate these currents from
other cationic components. However, the implication of such
currents in delayed after-depolarizations (DADs) has been
reported [72]. DADs are depolarizations that follow the action
potential. When sufficiently large and frequent, DADs can
induce additional action potentials and thus arrhythmias. DADs
occur because of the development of the calcium-dependant
transient inward current (Iti) induced by calcium waves, as have
been described to appear in SHR myocytes during the
development of hypertrophy [73]. Iti has been extensively
studied in cardiac cells and shown to have three components:
the Na+/Ca2+ exchanger, a [Ca2+]-activated chloride current and
a [Ca2+]-activated non-selective cation current [59]. In a rat
model of cardiac hypertrophy induced by injections of
isoproterenol, it has been shown that the incidence of DADs
increases with development of hypertrophy and that the Ca2+-
activated non-selective cationic component is responsible for an
estimated 13% of the overall amplitude of DADs [74]. TRPM4
appears as a good candidate for this last component. On that
note, it is important to point that the macroscopic non-selective
cationic component of Iti was detected in human atrial myocytes
but not in human ventricular cells [75]. This finding is in
accordance with our results. Indeed, in human atria, we detected
TRPM4 single channel currents but no current or only weakly
expressed current in normotensive rat ventricles [40,66]. Also,
in rat, TRPM4 mRNA expression was higher in atria than in
ventricles [41]. Thus, we hypothesize that TRPM4 may
participate in Iti in atrial but not ventricular normotensive rat
cardiomyocytes. On the other hand, TRPM4 may contribute to
this current component in hypertrophied ventricular cells and,
thus, participate in the increased appearance of DADs during
cardiac hypertrophy.
TRPM4 could also be implicated in the pro-arrhythmic early
after-depolarizations (EADs) that occur during the action
potential. These are associated with secondary Ca2+ release
from the SR and occur at depolarized potentials when the
TRPM4 current is supposed to be fully activated [76]. In that
sense, it has been reported that ventricular hypertrophy induces
EADs in rabbit [77]. It is important to mention that
depolarization induced by TRPM4 activation may, as was
specified for TRPC3, activate voltage-sensitive Ca2+-entry
pathways and thus contribute to the modifications of calcium
signalling seen during hypertrophy.
3.6. TRP channels and the end-point of heart failure
With the passage of time, compensated hypertrophy pro-
gresses to cardiac failure. As apoptotic cells are more abundant in
the failing than in the non-failing heart, it has been suggested that
apoptosis might be a mechanism involved in the development of
cardiac failure after hypertrophy [78]. It has been recently shown
that angiotensin II stimulation of cultured neonatal rat cardio-
myocytes transfected with the Ca2+-permeable TRPC7 channel
exhibited a significant increase in apoptosis due to activation of
the angiotensin II type 1 receptor [79]. Considering that the level
of angiotensin II is increased during hypertrophy, at least in SHR
[80], and that TRPC7 is abundantly expressed in heart [35], one
892 R. Guinamard, P. Bois / Biochimica et Biophysica Acta 1772 (2007) 885–894can postulate that the angiotensin II/TRPC7 link might be a key
mechanism in the process leading to heart failure following
cardiac hypertrophy.
It was also reported that TRPC6 mRNA expression was
augmented in hearts of human patients with dilated cardiomyo-
pathy compared with nonfailing hearts [52].
4. Conclusion
In conclusion, while mechanisms involved in cardiac
hypertrophy have been under investigation for a long time,
only a relatively small number of reports link the TRP family to
cardiac hypertrophy. This is due, however, to the fact that the
TRP proteins have only been recently cloned. The reports to the
present time should be regarded as the initial steps in a field that
is likely to expand significantly in the future. On this note, most
of the reports that associate TRPs to cardiac hypertrophy were
published at the end of 2006 [36–39,41,48,52,79]. The
development of specific pharmacological tools and of trans-
genic animal models for each TRP would help to elucidate their
function and confirm or identify those TRPs likely to serve as
therapeutic targets in the treatment of cardiac hypertrophy and
heart failure.
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